Maalox Plus Chewable Tablets 200mg/200mg/25mg
- Name:
Maalox Plus Chewable Tablets 200mg/200mg/25mg
- Company:
SANOFI
- Active Ingredients:
- Legal Category:
Supply through pharmacy only
Patient Information Leaflet Patient Information Leaflet last updated on medicines.ie: 29/10/19
(Click to Download)XPIL
PACKAGE LEAFLET: INFORMATION FOR THE USER
PACKAGE LEAFLET: INFORMATION FOR THE USER
1. What Maalox Plus Chewable Tablets are and what they are used for
1. What Maalox Plus Chewable Tablets are and what they are used for
2. What you need to know before you take Maalox Plus Chewable Tablets
2. What you need to know before you take Maalox Plus Chewable Tablets
3. How to take Maalox Plus Chewable Tablets
3. How to take Maalox Plus Chewable Tablets
4. Possible side effects
4. Possible side effects
5. How to store Maalox Plus Chewable Tablets
5. How to store Maalox Plus Chewable Tablets
6. Contents of the pack and other information
6. Contents of the pack and other information
Click on this link to Download PDF directly
SANOFI
Company Products
When a pharmaceutical company changes any document, a new version is published on medicines.ie. For each version, we show the dates it was published on medicines.ie and the reasons for change.
Updated on 30 October 2019 SmPC
Reasons for updating
- Change to section 4.5 - Interaction with other medicinal products and other forms of interaction
- Change to section 4.6 - Pregnancy and lactation
Legal category: Supply through pharmacy only
Updated on 29 October 2019 SmPC
Reasons for updating
- Change to section 4.5 - Interaction with other medicinal products and other forms of interaction
- Change to section 4.6 - Pregnancy and lactation
Legal category: Supply through pharmacy only
Updated on 29 October 2019 PIL
Reasons for updating
- New PIL for medicines.ie
Updated on 8 December 2017 SmPC
Reasons for updating
- New SmPC for new product
Legal category: Supply through pharmacy only
Updated on 8 December 2017 SmPC
Reasons for updating
- Change to section 4.5 - Interaction with other medicinal products and other forms of interaction
- Change to section 4.8 - Undesirable effects
- Change to section 10 - Date of revision of the text
Legal category: Supply through pharmacy only
Free text change information supplied by the pharmaceutical company
Section 4.5 added:-
Urine alkalinisation secondary to administration of magnesium hydroxide may modify excretion of some drugs; thus, increased excretion of salicylates has been seen.
Section 4.8 amendments:-
Immune system disorders - amended:-
Frequency unknown to Not known
Gastrointestinal disorders – added:-
Not known: abdominal pain
Metabolism and nutrition disorders
Added:- Very rare: hypermagnesemia including observations after prolonged administration to patients with renal impairment.
Amended:- from Frequency unknown to Not known:
Removed:- hypermagnesemia,
Updated on 5 December 2017 PIL
Reasons for updating
- New PIL for new product
Updated on 5 December 2017 PIL
Reasons for updating
- Change to section 2 - interactions with other medicines, food or drink
- Change to section 4 - possible side effects
- Change to section 6 - date of revision
Updated on 20 May 2015 PIL
Reasons for updating
- Change to name of manufacturer
Updated on 17 September 2014 PIL
Reasons for updating
- Change of contraindications
- Change to instructions about overdose
- Change to side-effects
- Change to further information section
Updated on 28 August 2014 SmPC
Reasons for updating
- Change to section 4.3 - Contraindications
- Change to section 4.4 - Special warnings and precautions for use
- Change to section 4.5 - Interaction with other medicinal products and other forms of interaction
- Change to section 4.6 - Pregnancy and lactation
- Change to section 4.8 - Undesirable effects
- Change to Section 4.8 – Undesirable effects - how to report a side effect
- Change to section 4.9 - Overdose
Legal category: Supply through pharmacy only
Free text change information supplied by the pharmaceutical company
Section 4.4 information included on intestinal obstruction and ileus in patients at higher risk such as those with renal impairment and information included on aluminium hydroxide not being well absorbed by the gastrointestinal tract.
Section 4.5 updated to include cefdinir and cefpodoxime. New paragraph on caution when concomitantly used with polystyrene sulfonate.
Section 4.6 updated to include 'Because of the limited maternal absorbtion when used as recommended, alumiunium hydroxide and magnesium sales combinations are considered as compatible with lactation.'
Section 4.8 updated to include immune system disorders and metabolism and nutrition disorders. PV Legislation wording included.
Section 4.9 new paragraphs on Signs and Symptoms and Management.
Updated on 6 November 2013 PIL
Reasons for updating
- Addition of manufacturer
Updated on 2 December 2011 SmPC
Reasons for updating
- Change to section 1 - Name of medicinal product
- Change to section 2 - Qualitative and quantitative composition
- Change to section 3 - Pharmaceutical form
- Change to section 6.1 - List of excipients
Legal category: Supply through pharmacy only
Free text change information supplied by the pharmaceutical company
Change of product name and formulation.
Updated on 30 November 2011 PIL
Reasons for updating
- Change of trade or active ingredient name
- Change of inactive ingredient
Updated on 10 May 2010 SmPC
Reasons for updating
- Change to section 1 - Name of medicinal product
Legal category: Supply through pharmacy only
Free text change information supplied by the pharmaceutical company
Updated on 6 May 2010 PIL
Reasons for updating
- Change of trade or active ingredient name
Updated on 2 September 2009 PIL
Reasons for updating
- Change due to user-testing of patient information
Updated on 1 September 2009 SmPC
Reasons for updating
- Change to section 4.4 - Special warnings and precautions for use
- Change to section 2 - Qualitative and quantitative composition
Legal category: Supply through pharmacy only
Free text change information supplied by the pharmaceutical company
Updated on 10 October 2008 PIL
Reasons for updating
- New PIL for medicines.ie
Updated on 8 October 2008 SmPC
Reasons for updating
- Correction of spelling/typing errors
Legal category: Supply through pharmacy only
Updated on 9 August 2007 SmPC
Reasons for updating
- Change to section 4.4 - Special warnings and precautions for use
- Change to section 4.5 - Interaction with other medicinal products and other forms of interaction
Legal category: Supply through pharmacy only
Free text change information supplied by the pharmaceutical company
Updated on 7 November 2006 SmPC
Reasons for updating
- Change to section 7 - Marketing authorisation holder
Legal category: Supply through pharmacy only
Free text change information supplied by the pharmaceutical company
Updated on 4 September 2006 SmPC
Reasons for updating
- Change to section 6.1 - List of excipients
Legal category: Supply through pharmacy only
Free text change information supplied by the pharmaceutical company
Updated on 27 July 2006 SmPC
Reasons for updating
- Improved electronic presentation
Legal category: Supply through pharmacy only
Updated on 5 January 2006 SmPC
Reasons for updating
- Change to section 2 - Qualitative and quantitative composition
- Change to section 6.1 - List of excipients
Legal category: Supply through pharmacy only
Updated on 29 September 2005 SmPC
Reasons for updating
- Change to section 2 - Qualitative and quantitative composition
- Change to section 10 - Date of revision of the text
Legal category: Supply through pharmacy only
Updated on 17 May 2005 SmPC
Reasons for updating
- Improved electronic presentation
Legal category: Supply through pharmacy only
Updated on 16 February 2005 SmPC
Reasons for updating
- Change to section 1 - Name of medicinal product
- Change to section 6.1 - List of excipients
- Change to section 10 - Date of revision of the text
Legal category: Supply through pharmacy only
Updated on 16 June 2003 SmPC
Reasons for updating
- New SPC for medicines.ie
Legal category: Supply through pharmacy only